about
Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part I: Overview, vaccines for enteric viruses and Vibrio choleraeVirulence-associated genome mutations of murine rotavirus identified by alternating serial passages in mice and cell cultures.Incorporation of a rotavirus vaccine into the national immunisation schedule in the United Kingdom: a review.New insights into rotavirus vaccines.The effectiveness of rotavirus vaccine in preventing acute gastroenteritis during rotavirus seasons among Polish children.Budget constraint and vaccine dosing: a mathematical modelling exercise.Impact of the national rotavirus vaccination programme on acute gastroenteritis in England and associated costs averted.Group A rotavirus universal mass vaccination: how and to what extent will selective pressure influence prevalence of rotavirus genotypes?Rotavirus vaccination in Brazil: effectiveness and health impact seven years post-introduction.Interference of Monovalent, Bivalent, and Trivalent Oral Poliovirus Vaccines on Monovalent Rotavirus Vaccine Immunogenicity in Rural Bangladesh.18β-glycyrrhetinic acid inhibits rotavirus replication in culture.Clinical Severity and Rotavirus Vaccination among Children Hospitalized for Acute Gastroenteritis in Belém, Northern Brazil.Rapid Declines in Age Group-Specific Rotavirus Infection and Acute Gastroenteritis Among Vaccinated and Unvaccinated Individuals Within 1 Year of Rotavirus Vaccine Introduction in England and Wales.Group a rotavirus and norovirus genotypes circulating in the northeastern Brazil in the post-monovalent vaccination era.Rotavirus strain surveillance for three years following the introduction of rotavirus vaccine into Belém, Brazil.Rotavirus Vaccines: a story of success with challenges ahead.Rotavirus type profile in nosocomial and community infections in Western Slovakia.Diversity of rotavirus strains circulating in Northern Brazil after introduction of a rotavirus vaccine: high prevalence of G3P[6] genotype.Rotarix in Japan: Expectations and ConcernsImmune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial
P2860
Q27004488-1D2629E8-AEC6-4343-BE21-2E2AC47B2EDAQ33602861-7CDA6BE4-EE16-4912-9759-B20CB8F5236BQ34374858-6C9C3EBC-AE43-4B41-8152-3CDFED7DADF8Q36552854-CF38E4FD-9DB0-44BD-8529-9259FDA7A02FQ36958313-FC95FBB5-4575-46F6-9171-E017557E834FQ37522192-B0256BC0-57AF-4D5A-A4EF-311AA35B84BAQ37607887-9F9D0C3D-983F-478E-B26F-B4AF11A1E4B5Q38068232-37C4436C-8D1A-4E24-A7A5-A6687913B345Q38168901-1415500A-B3B4-459B-8960-81CC6C5625A2Q38501139-4F7232C1-88A5-4D02-8191-E8075A8367E2Q39344325-C9CE1A6B-B9A8-487E-B0E9-499C15973FC8Q39991868-834DB1B8-5F74-4010-9D80-CEF93EFFEEBEQ40671330-BE285167-4BBE-4604-BFE2-B7943337F49BQ40930830-FBA8CE18-87E1-403C-A4FF-58C41804D6E0Q41329103-2C2B8766-4B8A-45FB-A016-27A7226D2A82Q41589121-F5E6553E-9DB1-4066-8A21-0985A0080314Q41691553-20D20A7B-E399-4EE1-BFC8-4EC3C661BC3AQ42261568-AC78FA6B-4704-4739-956E-B898776F8D73Q42775398-7BCF4C29-A7A4-4B63-963D-6ABF047CB68AQ56337574-1E376635-0D25-4FC8-8E89-872248392060
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Rotarix®: vaccine performance 6 years postlicensure.
@en
Rotarix®: vaccine performance 6 years postlicensure.
@nl
type
label
Rotarix®: vaccine performance 6 years postlicensure.
@en
Rotarix®: vaccine performance 6 years postlicensure.
@nl
prefLabel
Rotarix®: vaccine performance 6 years postlicensure.
@en
Rotarix®: vaccine performance 6 years postlicensure.
@nl
P2860
P356
P1476
Rotarix®: vaccine performance 6 years postlicensure.
@en
P2093
Alexandre C Linhares
Miguel O'Ryan
P2860
P304
P356
10.1586/ERV.11.152
P50
P577
2011-12-01T00:00:00Z